Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

U.S. Firm Licenses Cuban Drug Candidates

July 19, 2004 | A version of this story appeared in Volume 82, Issue 29

Though U.S. government policy is to discourage trade with Cuba, a California biotechnology company, CancerVax, has received approval from the Department of Treasury's Office of Foreign Asset Control to license three cancer drugs from CIMAB, the commercialization arm of Cuba's Center of Molecular Immunology in Havana. CancerVax will pay approximately $6 million in access and technology payments over the next three years for the three drug candidates, which target the epidermal growth factor receptor signaling pathway for treatment of cancers such as non-small-cell lung, breast, bladder, pancreatic, and other cancers. If approved for commercialization, CancerVax will pay up to an additional $35 million. A condition of government approval was that the $6 million in technology payment be made in U.S.-origin food, medicines, or medical supplies. After commercialization, half the payments may be made in cash.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.